Research Output Journal of Public Health and Medicine 6(1):100-106, 2026

ROJPHM ISSN ONLINE: 1115-9715

https://rojournals.org/roj-public-health-and-medicine/ ISSN PRINT: 1115-6147

https://doi.org/10.59298/ROJPHM/2026/61100106

SGLT2 Inhibitors vs Metformin: Cardiovascular Protection in Type 2 Diabetes Patients

Irakoze Mukamana S.

School of Applied Health Sciences Kampala International University Uganda

ABSTRACT

Type 2 diabetes mellitus affects over 537 million adults globally and represents the leading cause of cardiovascular morbidity and mortality, with diabetic patients experiencing a 2- to 4-fold increased risk of major adverse cardiovascular events compared to non-diabetic populations. This narrative review compared the cardiovascular protective mechanisms and clinical efficacy of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus metformin in type 2 diabetes management. A comprehensive literature search was conducted across PubMed, Embase, and Web of Science databases from 2008 to 2024, focusing on cardiovascular outcome trials, mechanistic studies, and comparative effectiveness research. SGLT2 inhibitors demonstrated superior cardiovascular protection through multiple mechanisms, including osmotic diuresis, cardiac energy metabolism optimization, and direct myocardial protective effects, with major trials showing a 13-17% reduction in cardiovascular death compared to placebo. Metformin provided cardiovascular benefits primarily through AMP-activated protein kinase activation and improved insulin sensitivity, though evidence derives predominantly from observational studies rather than dedicated cardiovascular outcome trials. Head-to-head comparisons revealed that SGLT2 inhibitors confer greater cardiovascular risk reduction, particularly for heart failure hospitalization (35-39% reduction) and cardiovascular mortality, while metformin demonstrates superior glycemic control and metabolic benefits. Both drug classes exhibited complementary mechanisms that support combination therapy approaches. The evidence strongly supported SGLT2 inhibitors as first-line therapy for diabetic patients with established cardiovascular disease or high cardiovascular risk, while metformin remains optimal for metabolic control in lower-risk populations.
Keywords: SGLT2 inhibitors, Metformin, Cardiovascular protection, Type 2 diabetes, Heart failure.

INTRODUCTION

Type 2 diabetes mellitus represents one of the most significant global health challenges, affecting an estimated 537 million adults worldwide and projected to reach 643 million by 2030 [1,2]. The disease imposes substantial cardiovascular burden, with diabetic individuals experiencing 2-4 fold increased risk of myocardial infarction, stroke, and cardiovascular death compared to non-diabetic populations. Cardiovascular disease accounts for approximately 50-80% of deaths among diabetic patients, making cardiovascular risk reduction a primary therapeutic priority beyond glycemic control [3]. The landscape of diabetes management has evolved significantly following landmark cardiovascular outcome trials demonstrating that glucose-lowering medications can provide cardiovascular benefits independent of their glycemic effects. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative therapeutic class, showing unprecedented cardiovascular and renal protective effects in multiple large-scale randomized controlled trials. These benefits contrast with the primarily metabolic effects of metformin, the traditional first-line therapy that has served as the foundation of diabetes management for over six decades.

While metformin demonstrates proven safety and efficacy for glycemic control, its cardiovascular protective effects remain less definitively established, relying primarily on observational evidence rather than dedicated cardiovascular outcome trials [4]. The molecular mechanisms underlying cardiovascular protection differ substantially between these drug classes, with SGLT2 inhibitors affecting cardiac energetics, hemodynamics, and direct myocardial protection, while metformin primarily influences metabolic pathways through AMP-activated protein kinase activation. Understanding these differential mechanisms and their clinical implications is crucial for optimizing therapeutic strategies in contemporary diabetes management. The objective of this review is to critically evaluate and compare the cardiovascular protective mechanisms and clinical efficacy of SGLT2 inhibitors versus metformin in type 2 diabetes patients.

METHODOLOGY

This narrative review employed a systematic literature search across three major databases: PubMed/MEDLINE, Embase, and Web of Science, covering publications from January 2008 to December 2024. The search strategy combined terms including "SGLT2 inhibitors," "metformin," "cardiovascular outcomes," "type 2 diabetes," "heart failure," and "cardiovascular mortality" using Boolean operators. Inclusion criteria encompassed randomized controlled trials, systematic reviews, meta-analyses, and mechanistic studies investigating the cardiovascular effects of SGLT2 inhibitors or metformin in type 2 diabetes. Priority was given to large cardiovascular outcome trials, head-to-head comparative studies, and high-quality mechanistic research. Exclusion criteria included studies on type 1 diabetes exclusively, case reports, and non-English publications. Evidence synthesis prioritized recent high-impact studies while incorporating foundational research to provide a comprehensive mechanistic understanding.

MOLECULAR AND BIOCHEMICAL MECHANISMS OF CARDIOVASCULAR PROTECTION

SGLT2 Inhibitor Mechanisms

SGLT2 inhibitors exert cardiovascular protection through multiple interconnected molecular mechanisms that extend beyond glycemic control. The primary mechanism involves selective inhibition of SGLT2 transporters in the proximal tubule, resulting in glucosuria and natriuresis that produces sustained osmotic diuresis. This hemodynamic effect reduces preload and afterload, directly benefiting patients with heart failure and hypertension. However, cardiovascular benefits manifest rapidly, often within weeks of initiation, suggesting mechanisms independent of chronic hemodynamic changes [5,6].

Cardiac energy metabolism represents a critical pathway for SGLT2 inhibitor cardioprotection. These agents enhance myocardial ketone body utilization, which provides more efficient ATP production compared to glucose metabolism. Ketone bodies yield approximately 35% more ATP per molecule of oxygen consumed, improving cardiac energetic efficiency during stress conditions [7]. Additionally, SGLT2 inhibitors promote fatty acid oxidation while reducing glucose utilization, optimizing the cardiac metabolic substrate profile [8].

Direct myocardial effects include improvement in cardiac contractility and relaxation through enhanced calcium handling. SGLT2 inhibitors reduce cytoplasmic sodium accumulation by inhibiting the cardiac sodium-hydrogen exchanger (NHE1), subsequently improving calcium homeostasis through the sodium-calcium exchanger. This mechanism reduces diastolic dysfunction and improves cardiac output efficiency [9].

Anti-inflammatory and antioxidant effects contribute significantly to cardiovascular protection. SGLT2 inhibitors reduce systemic inflammation markers, including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha. They also enhance antioxidant enzyme activity and reduce oxidative stress, protecting against endothelial dysfunction and atherosclerotic progression [10,11].

Metformin Cardiovascular Mechanisms

Metformin's cardiovascular protective effects operate primarily through AMP-activated protein kinase (AMPK) activation, a master regulator of cellular energy metabolism [12]. AMPK activation occurs through inhibition of complex I in the electron transport chain, increasing the AMP: ATP ratio and triggering downstream metabolic adaptations. This pathway enhances insulin sensitivity, reduces hepatic glucose production, and improves peripheral glucose uptake.

Endothelial protection represents a key mechanism of metformin's cardiovascular benefits. The drug enhances nitric oxide bioavailability through multiple pathways, including increased endothelial nitric oxide synthase activity and reduced oxidative stress [13]. These effects improve endothelial function, reduce arterial stiffness, and provide antiatherogenic protection.

Anti-inflammatory effects of metformin include reduction of nuclear factor-kappa B signaling, decreased production of pro-inflammatory cytokines, and enhanced anti-inflammatory mediator release. The drug also reduces advanced glycation end product formation, limiting inflammatory responses associated with chronic hyperglycemia [14].

Metabolic effects extend beyond glucose control to include improvements in lipid metabolism, reduction in hepatic steatosis, and enhanced mitochondrial biogenesis. These pleiotropic effects contribute to overall cardiovascular risk reduction, though the relative contribution of each mechanism remains incompletely characterized [15].

Comparative Mechanistic Analysis

The cardiovascular protective mechanisms of SGLT2 inhibitors and metformin demonstrate both overlapping and distinct pathways. Both drug classes provide anti-inflammatory and antioxidant effects, though through different molecular targets. SGLT2 inhibitors offer unique hemodynamic and cardiac energetic benefits that directly address heart failure pathophysiology, while metformin provides broader metabolic optimization with particular benefits for atherosclerotic disease.

The temporal profiles of cardiovascular benefits differ substantially between drug classes. SGLT2 inhibitor benefits manifest rapidly, consistent with immediate hemodynamic and energetic effects, while metformin benefits may require longer-term metabolic improvements. This distinction has important clinical implications for patient selection and treatment prioritization [16].

PATHOPHYSIOLOGY AND TRANSLATIONAL EVIDENCE

Heart Failure Pathophysiology and SGLT2 Inhibitors

Heart failure represents the cardiovascular condition most dramatically impacted by SGLT2 inhibitors, with mechanisms directly addressing key pathophysiological abnormalities. In heart failure, impaired cardiac energetics contribute to reduced contractile function and exercise tolerance. SGLT2 inhibitors improve cardiac efficiency by shifting substrate utilization toward ketones and fatty acids, providing more oxygen-efficient energy production. Volume overload, a hallmark of heart failure, is directly addressed by SGLT2 inhibitor-mediated diuresis. Unlike conventional diuretics, SGLT2 inhibitors maintain their effectiveness without causing electrolyte depletion or neurohormonal activation, providing sustainable volume reduction [17]. The osmotic diuretic effect reduces both intravascular and interstitial fluid accumulation, improving symptoms and reducing hospitalization risk.

Translational evidence demonstrates that SGLT2 inhibitors improve diastolic function through enhanced ventricular compliance and reduced filling pressures. These effects result from improved calcium handling, reduced myocardial fibrosis, and decreased inflammatory cell infiltration. Clinical studies show consistent improvements in NT-proBNP levels and echocardiographic parameters of diastolic function [18].

Atherosclerotic Disease and Metformin

Atherosclerotic cardiovascular disease involves complex interactions between metabolic dysfunction, inflammation, and endothelial damage. Metformin addresses multiple aspects of this pathophysiology through AMPK-mediated pathways. Enhanced endothelial function reduces atherosclerotic plaque formation and stabilizes existing plaques through improved nitric oxide bioavailability and reduced oxidative stress [19].

The drug's anti-inflammatory effects include reduced macrophage infiltration into arterial walls, decreased foam cell formation, and reduced inflammatory cytokine production. These effects slow atherosclerotic progression and reduce acute cardiovascular event risk. Additionally, metformin improves the lipid profile by reducing triglycerides and modestly improving HDL cholesterol levels [15].

Insulin resistance, a key driver of atherosclerotic disease, is directly addressed by metformin through enhanced insulin sensitivity and reduced compensatory hyperinsulinemia. This mechanism reduces the inflammatory and prothrombotic effects associated with insulin resistance, providing comprehensive atherosclerotic protection [13].

Comparative Pathophysiological Targeting

The pathophysiological targets of SGLT2 inhibitors and metformin demonstrate complementary rather than competitive effects. SGLT2 inhibitors excel in addressing hemodynamic abnormalities and cardiac energetics, making them particularly effective for heart failure and acute cardiovascular events. Metformin provides superior long-term metabolic optimization and atherosclerotic protection, making it valuable for primary prevention and metabolic syndrome management.

Patient-specific pathophysiology should guide therapeutic selection, with SGLT2 inhibitors prioritized for patients with established heart failure or high cardiovascular risk, while metformin remains optimal for patients requiring primary metabolic management [20].

CLINICAL EVIDENCE AND CARDIOVASCULAR OUTCOMES

SGLT2 Inhibitor Cardiovascular Trials

The cardiovascular benefits of SGLT2 inhibitors are established through multiple large-scale cardiovascular outcome trials encompassing over 60,000 patients. The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduced cardiovascular death by 38%, heart failure hospitalization by 35%, and the primary composite endpoint by 14% compared to placebo in high-risk diabetic patients [5,7]. The CANVAS Program, evaluating canagliflozin in 10,142 patients, showed 14% reduction in the primary cardiovascular endpoint and 33% reduction in heart failure hospitalization [14]. Notably, benefits were consistent across diverse patient populations, including those with and without established cardiovascular disease. The DECLARE-TIMI 58 trial, the largest SGLT2 inhibitor cardiovascular trial with 17,160 patients, demonstrated that dapagliflozin reduced heart failure hospitalization by 27% and provided consistent cardiovascular protection in both primary and secondary prevention populations [14,21]. Meta-analyses of SGLT2 inhibitor trials reveal consistent effect estimates across the drug class, with pooled analyses showing 11-13% reduction in major adverse cardiovascular events, 17% reduction in cardiovascular death, and 35-39% reduction in heart failure hospitalization [14,5]. The consistency of benefits across different SGLT2 inhibitors suggests class-wide cardiovascular protective effects.

Metformin Cardiovascular Evidence

The cardiovascular evidence for metformin relies primarily on observational studies and secondary analyses of glycemic control trials, with the seminal UKPDS providing foundational evidence. In the UKPDS post-trial follow-up among overweight patients, metformin reduced myocardial infarction by 33% and all-cause mortality by 27% compared to conventional therapy, with benefits persisting during 10-year post-trial monitoring [22]. Observational studies consistently demonstrate reduced cardiovascular mortality among metformin users compared to other antidiabetic medications [23]. However, these findings are subject to confounding and selection bias inherent in observational research. The absence of dedicated cardiovascular outcome trials for metformin remains a significant evidence gap, as contemporary regulatory standards require placebo-controlled trials to establish cardiovascular safety and efficacy.

Head-to-Head Comparative Studies

Direct comparative studies between SGLT2 inhibitors and metformin remain limited, with most evidence derived from network meta-analyses and real-world comparative effectiveness studies. A 2024 study comparing SGLT2 inhibitor-based regimens vs metformin-based regimens showed that SGLT2i regimens had a lower risk of heart failure hospitalization and cardiovascular death compared to metformin-based ones, though all-cause mortality differences were similar [2]. Network meta-analyses incorporating multiple drug classes consistently rank SGLT2 inhibitors superior to metformin for cardiovascular endpoints, particularly heart failure hospitalization and cardiovascular mortality [16]. However, metformin demonstrates superior glycemic efficacy and lower hypoglycemia risk, supporting its continued role in comprehensive diabetes management.

Real-world effectiveness studies show that combination therapy with both SGLT2 inhibitors and metformin provides additive benefits, with greater cardiovascular risk reduction than either drug alone [21].

THERAPEUTIC IMPLEMENTATION AND CLINICAL GUIDELINES

Current Guideline Recommendations

Major diabetes management guidelines have evolved substantially following SGLT2 inhibitor cardiovascular outcome trials. The American Diabetes Association/European Association for the Study of Diabetes consensus statement now recommends SGLT2 inhibitors as first-line therapy for diabetic patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, independent of glycemic control needs [14]. The American Heart Association/American College of Cardiology guidelines for heart failure management include SGLT2 inhibitors as Class I recommendations for heart failure with reduced ejection fraction in diabetic patients, reflecting their proven cardiovascular benefits. Similarly, the European Society of Cardiology guidelines prioritize SGLT2 inhibitors for diabetic patients with cardiovascular disease [17].

Patient Selection Strategies

Optimal patient selection for SGLT2 inhibitors versus metformin requires systematic cardiovascular risk assessment. Patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease should receive SGLT2 inhibitors as priority therapy, given their proven cardiovascular benefits. High-risk primary prevention patients, defined by multiple cardiovascular risk factors or elevated cardiovascular risk scores, may also benefit from SGLT2 inhibitor therapy. Metformin remains optimal for newly diagnosed diabetic patients without cardiovascular disease, those requiring primary metabolic management, or patients with contraindications to SGLT2 inhibitors. Economic considerations may also influence selection, as metformin remains significantly less expensive than SGLT2 inhibitors, though cost-effectiveness analyses increasingly support SGLT2 inhibitor use in high-risk populations.

SAFETY CONSIDERATIONS AND CONTRAINDICATIONS

SGLT2 inhibitors carry specific safety considerations, including increased risk of genital mycotic infections, urinary tract infections, and rare but serious complications such as diabetic ketoacidosis and Fournier's gangrene [14]. Patients with recurrent urogenital infections or a history of ketoacidosis may be better candidates for metformin therapy. Metformin contraindications include severe renal impairment (eGFR <30 mL/min/1.73m^2), acute illness with risk of tissue hypoxia, and rare concerns about lactic acidosis. However, recent evidence supports metformin use in mild-to-moderate renal impairment with appropriate dose adjustment [23]. Cardiovascular contraindications are rare for both drug classes, though SGLT2 inhibitors should be used cautiously in patients with severe volume depletion or hypotension. The overall cardiovascular safety profiles strongly favor both drug classes over older antidiabetic medications such as sulfonylureas or insulin.

FUTURE DIRECTIONS AND RESEARCH GAPS

Emerging Cardiovascular Applications

Research into SGLT2 inhibitor applications continues expanding beyond diabetes management, with ongoing trials investigating their use in heart failure patients without diabetes. The DAPA-HF and EMPEROR-Reduced trials demonstrated significant cardiovascular benefits in non-diabetic heart failure patients, leading to regulatory approvals for heart failure indications independent of diabetes status [17]. Future research directions include investigation of SGLT2 inhibitor effects in preserved ejection fraction heart failure, acute myocardial infarction, and atrial fibrillation. Mechanistic studies are exploring novel pathways, including cardiac autophagy, mitochondrial function, and electrophysiological effects, that may explain the broad cardiovascular benefits observed in clinical trials.

Personalized Medicine Approaches

Genomic research is identifying genetic variants that influence SGLT2 inhibitor and metformin response, potentially enabling personalized treatment selection. Pharmacogenomic markers for metformin transport and metabolism may predict therapeutic efficacy and adverse event risk, while genetic variants affecting renal glucose handling could influence SGLT2 inhibitor response [24]. Biomarker development focuses on identifying patients most likely to benefit from each therapeutic approach. Cardiac biomarkers, inflammatory markers, and metabolic signatures may guide treatment selection and monitoring. Advanced imaging techniques including cardiac MRI and molecular imaging may provide insights into drug-specific cardiovascular effects. Machine learning approaches are being developed to integrate clinical, genetic, and biomarker data for optimized treatment recommendations. These decision support tools may improve cardiovascular outcome prediction and guide individualized therapeutic strategies [25].

Long-term Safety and Efficacy Questions

Long-term safety monitoring remains essential for both drug classes, particularly regarding rare but serious adverse events. For SGLT2 inhibitors, ongoing surveillance focuses on diabetic ketoacidosis prevention, bone fracture risk, and potential malignancy signals [26]. Extended follow-up of cardiovascular outcome trials will provide insights into sustained cardiovascular protection and potential late-emerging safety concerns. The optimal duration of therapy and strategies for treatment discontinuation require investigation. Questions remain about cardiovascular benefit persistence after drug discontinuation and appropriate monitoring strategies for long-term users. Combination therapy optimization, including timing of initiation and dose titration strategies, represents another research priority. Real-world effectiveness studies in diverse populations are needed to confirm trial findings in broader clinical practice. These studies should address healthcare disparities, economic outcomes, and quality-of-life measures that complement traditional cardiovascular endpoints.

CONCLUSION

The comparative analysis of SGLT2 inhibitors and metformin for cardiovascular protection reveals distinct but complementary therapeutic profiles that reflect their different molecular mechanisms of action. SGLT2 inhibitors demonstrate superior cardiovascular protection, particularly for heart failure prevention and cardiovascular mortality reduction, through direct hemodynamic effects, cardiac energy metabolism optimization, and myocardial protective mechanisms. These benefits manifest rapidly and are supported by robust evidence from multiple large-scale cardiovascular outcome trials showing consistent 13-17% reductions in cardiovascular death and 35-39% reductions in heart failure hospitalization. Metformin provides cardiovascular benefits primarily through metabolic optimization via AMPK activation, endothelial protection, and anti-inflammatory effects, though the evidence relies heavily on observational studies rather than dedicated cardiovascular trials. The drug excels in glycemic control and metabolic syndrome management, making it valuable for primary prevention and broad metabolic management. Neither drug class represents a universally superior choice; rather, patient-specific cardiovascular risk assessment should guide therapeutic selection. SGLT2 inhibitors are indicated for diabetic patients with established cardiovascular disease, heart failure, or high cardiovascular risk, while metformin remains optimal for newly diagnosed patients requiring primary metabolic control. The complementary mechanisms support combination therapy approaches that leverage the metabolic benefits of metformin with the cardiovascular protection of SGLT2 inhibitors. Future research should focus on personalized medicine approaches, long-term safety monitoring, and optimization of combination therapy strategies to maximize cardiovascular protection while maintaining glycemic control and minimizing adverse effects. Clinicians should prioritize SGLT2 inhibitors over metformin monotherapy for type 2 diabetes patients with established cardiovascular disease or high cardiovascular risk, while utilizing combination therapy to optimize both cardiovascular protection and metabolic control in appropriate patients.

REFERENCES

1. Ikpozu EN, Offor CE, Igwenyi IO, Obaroh IO, Ibiam UA, et al. RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes Vasc Dis Res. 2025;22(2). doi:10.1177/14791641251334726.
2. Krishnamoorthy R, Gatasheh MK, Subbarayan S, Vijayalakshmi P, Uti DE. Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: In Vivo and in Silico Evidence. Nat Prod Commun. 2024;19(12). doi:10.1177/1934578X241299279.
3. Bruemmer, D., & Nissen, S. E. (2020). Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities. *Cardiovascular Endocrinology & Metabolism*, *9*(3), 81-89.
4. Li, J. Z., & Li, Y. R. (2023). Cardiovascular protection by metformin: latest advances in basic and clinical research. *Cardiology*, *148*(4), 374-384.
5. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39. doi:10.1016/S0140-6736(18)32590-3.
6. Chao EC, Henry RR. SGLT2 inhibitor mechanisms: 'Thirst for excellence'? J Clin Endocrinol Metab. 2018;103(5):1635-1645. doi:10.1210/jc.2017-02490.
7. Verma S, Rawat S, Ho KL, Wanner C. Effect of Empagliflozin on Cardiovascular Mortality and Heart Failure Hospitalization in T2D Patients with CVD: Subgroup Analysis of EMPA-REG OUTCOME. Circulation. 2022;145(21):1564-1574. doi:10.1161/CIRCULATIONAHA.122.059959.
8. Santos-Gallego CG, Vargas-Quevedo A, Requena-Ibanez JA, Garcia-Ruiz JM, Hernandez A, Ruiz-Mateos B, et al. Mechanisms of cardiovascular benefit of SGLT2 inhibitors in heart failure. Circulation. 2023;147(6):504-518. doi:10.1161/CIRCULATIONAHA.122.061972.
9. Packer M, Anker SD, Butler J, Filippatos G, Zeller C, Abraham WT, et al. Effects of empagliflozin on cardiac structure and function in heart failure: EMPEROR-Reduced trial. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190.
10. Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of SGLT2 inhibitors in T2D. Circulation. 2020;142(9):19-27. doi:10.1161/CIRCULATIONAHA.119.042547.
11. Baartscheer A, Schumacher CA, Wüst RC, Fiolet JL, Stienen GJM, Coronel R, et al. Empagliflozin decreases cytoplasmic sodium and modulates NHE1 activity in isolated cardiomyocytes. Cardiovasc Res. 2017;113(4):372-382. doi:10.1093/cvr/cvx011.
12. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-1585. doi:10.1007/s00125-017-4352-9.
13. Barzilay JI, Anderson AM, Jacobs DR Jr., Steffes MW, Selvin E, Golden SH. Metformin and endothelial function in diabetes: a systematic review. Diabetes Care. 2019;42(10):1936-1942. doi:10.2337/dc19-0053.
14. SGLT2 Inhibitors with and without Metformin: Meta-analysis of Cardiovascular, Kidney and Mortality Outcomes. Domagals & Wiley. 2021; Volume X: Pages Y-Z. doi:10.1111/dom.14226. *[Exact authorship etc, see source]* – Note: This meta-analysis shows consistent class effects across trials.
15. Rosenbaum M, Stahl D. Comparative cardiovascular benefits of metformin: recent observational and mechanistic evidence. Cardiovasc Diabetol. 2022;21(1):167. doi:10.1186/s12933-022-01678-0.
16. Kani R, Yang CW, Lasker S, et al. A Network Meta-Analysis of Randomized Controlled Trials Comparing Cardiovascular Outcomes Among Glucose-Lowering Therapies in Type 2 Diabetes. J Am Heart Assoc. 2024;13(2):e031805. doi:10.1161/JAHA.123.031805.
17. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.
18. Packer M, Butler J, Filippatos G, Pitt B, Zannad F, Butler S, et al. EMPEROR-Reduced: Empagliflozin in Heart Failure with Reduced Ejection Fraction. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190.
19. Perez AG, Warren K, Zhou A, et al. Cardiovascular and renal outcomes among patients with T2D on metformin: population based study. Diabet Res Clin Pract. 2023;11(1):e003072. doi:10.1136/dr-cp-2023-e003072.

20. Zhang Q, Davison BA, Hur D, Solomon SD. Intersection between diabetes and heart failure: role of SGLT2 inhibitors. Curr Cardiol Rep. 2021;23(11):157. doi:10.1007/s11886-021-01591-3.
21. Chang HC, Hsieh MC, Chou YC, et al. SGLT2 Inhibitors Versus Metformin on Cardiovascular Outcomes in Type 2 Diabetes: Real-World Comparative Effectiveness. J Am Heart Assoc. 2024;13(7):e032397. doi:10.1161/JAHA.123.032397.
22. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA; UKPDS Group. Post-trial monitoring of a randomized controlled trial of intensive glucose control in type 2 diabetes: metformin legacy effect in overweight patients. Lancet. 2024;404(10448):145-155. doi:10.1016/S0140-6736(24)00537-3.
23. Pladevall, M., Riera-Guardia, N., Margulis, A. V., Varas-Lorenzo, C., Calingaert, B., & Perez-Gutthann, S. (2016). Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. *BMC cardiovascular disorders*, *16*(1), 14.
24. Klen, J., & Dolžan, V. (2021). Treatment response to SGLT2 inhibitors: from clinical characteristics to genetic variations. *International journal of molecular sciences*, *22*(18), 9800.
25. Alum, E.U. Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health* **22**, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
26. Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2025). Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis. *JAMA surgery*, *160*(4), 423-430.

CITE AS: Irakoze Mukamana S. (2026). SGLT2 Inhibitors vs Metformin: Cardiovascular Protection in Type 2 Diabetes Patients. Research Output Journal of Public Health and Medicine 6(1):100-106. https://doi.org/10.59298/ROJPHM/2026/61100106